Lisata halts XOWNA FREEDOM Trial; development now contingent on partner

LISATA THERAPEUTICS, INC.

Phase 2b FREEDOM Trial of XOWNA (autologous CD34+ cells) suspended May 2022 due to COVID enrollment challenges and heterogeneity.
Interim analysis of first 20 patients with 6-month follow-up completed; board decided redesigned trial is needed but prohibitively expensive alone.
XOWNA development will only continue if a strategic partner is identified and secured to fund a redesigned trial.
No assurance that a partner can be found or that acceptable terms will be reached.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.